Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Colorectal Neoplasms 29Prostatic Neoplasms 28Neoplasms 28Breast Neoplasms 27Neoplasm Metastasis 26Multiple Myeloma 24Pancreatic Neoplasms 22Recurrence 18Ovarian Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Melanoma 17Lymphoma, Non-Hodgkin 17Triple Negative Breast Neoplasms 16Lymphoma, Large B-Cell, Diffuse 15Leukemia, Myeloid, Acute 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Burkitt Lymphoma 14Lung Neoplasms 13Carcinoma, Renal Cell 13Stomach Neoplasms 12Lymphoma, Follicular 12Lymphoma 12Endometrial Neoplasms 12Advanced Solid Tumors 12Small Cell Lung Carcinoma 11Glioblastoma 11Colonic Neoplasms 11Leukemia, Lymphocytic, Chronic, B-Cell 10Uterine Cervical Neoplasms 9

Interventions

durvalumab 1Pemetrexed 1Paclitaxel 1Gemcitabine 1Cisplatin 1Carboplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pathologic Complete Response × 30 days × Clear all
NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡